Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Pancreatic cancer is notoriously hard to catch early — but two new blood tests are showing real promise. The PANXEON assay, combining microRNA signals and CA19-9, hit 91.7% accuracy in detecting early-stage disease. Separately, a high-sensitivity ddPCR test targeting KRAS mutations outperformed standard sequencing, catching cancer signs nearly four times more often at diagnosis and revealing a hidden group of high-risk patients.
Pancreatic cancer kills more than any other common cancer largely because it's almost always caught too late — over 75% of cases are diagnosed after the disease has already spread. Two new liquid biopsy studies are now offering a potential path to earlier detection, and the results are turning heads.
The first, published in Nature Medicine, introduces PANXEON — a blood test combining circulating and exosomal microRNA signatures with the established biomarker CA19-9. Tested across 1,649 patients from the US, Japan, Italy, and South Korea, PANXEON achieved an AUROC of 91.7% in distinguishing early-stage pancreatic ductal adenocarcinoma (PDAC) and precancerous high-grade dysplasia from controls. It also showed 83.8% sensitivity for stage I/II disease and minimal cross-reactivity with other GI cancers.
The second study, published in Clinical Cancer Research, found that a high-sensitivity ddPCR assay targeting KRAS mutations (G12D, G12V, G12R) detected cancer-related ctDNA in nearly four times as many patients as standard next-generation sequencing at diagnosis — and continued outperforming NGS after chemotherapy and surgery.
By the Numbers:
Why it matters: Both tests could help identify high-risk patients earlier — when treatment is still possible — and may eventually guide the use of emerging KRAS-targeted therapies like daraxonrasib. Larger prospective trials are still needed before either becomes standard practice.
